|
We just wrapped up the JPM miniseries we recorded in January, and that got me thinking about a couple of other miniseries ideas I've been mulling. How about a few episodes of deep discussion between biopharmas and their outsourcing partners? I know CDMOs would be eager, but would sponsor companies be willing to come on and share about selection, contracting, obligations, responsibilities, challenges, etc.?
I've also had a few requests for more episodes like this one on commercialization with Boehringer Ingelheim's Carine Boustany. We've always been focused on new/emerging biopharmas, but I think some commercialization talk would be fresh and instructive. If you have outsourcing and/or commercialization stories to share, please get in touch with me at matt.pillar@lifescienceconnect.com.
I hope you're enjoying the newsletter. One listener who subscribed to it left the Business of Biotech podcast a five-star review in iTunes, but went on to lament the newsletter as having too many headlines, being poorly formatted, and packed with jargon. I'm confident that person isn't reading this, because they subscribed to the wrong newsletter.
Tell me what you love and what you don't. Send me a guest or topical idea. I'd love to hear from you and my email is right up there.
- Matt Pillar, Business of Biotech host and chief editor, Bioprocess Online
|
|
|
|
|
Biotech Beat
|
March 21, 2023
|
|
|
![]() |
|
|
|
by RICH RAMKO & ASHWIN SINGHANIA
|
|
Allan Shaw isn't the only insider we rely on for biopharma partnership prognostication. Over at Bioprocess Online, we turn regularly to EY (that's the new Ernst & Young, for those of a certain vintage), whose analysts and consultants aren't as boring as their CPAs. Here, they offer some bright spots while hedging their bets with some conservative advice on capital preservation and milestones (i.e., a candidate in the pipeline beats two in R&D).
|
|
READ NOW →
|
|
![]() |
|
|
|
by BEN COMER
|
|
2022 Nobel Prize winner Carolyn Bertozzi, Ph.D., was at an event when she realized she forgot her phone charger. A stranger named Dr. José Mejía Oneto let her borrow his. They're not strangers anymore. Today, she's helping him lead a click chemistry startup called Shasqi. Life Science Leader chief editor Ben Comer tells us what Bertozzi the scientist taught Mejía Oneto the doctor about the business of biotech.
|
|
READ NOW →
|
|
|
![]() |
|
|
|
by MATT PILLAR
|
|
Since I wrote this article a couple weeks back, I'm getting more pitches to be on the podcast from real biopharmas and fewer from what my buddy Jon O'Connell refers to as "BINOs" (biotechs in name only). Mission accomplished. It's a quick read, three parts instructive to one part rant, but can I get an "amen!" from our biopharma purists?
|
|
READ NOW →
|
|
![]() |
|
|
|
by MATT PILLAR
|
|
From The Archives: DaVinci had a quill. Chris Gibson, Ph.D., has artificial intelligence. On episode 129 of the Business of Biotech, Gibson confidently updates us on the quest underway at Recursion, the company he leads as CEO. They're building a map of human biology. Just as Google did with the earth, only smaller. And much, much more complex.
|
|
LISTEN NOW →
|
|
|
|
|
"I've got a mom, two sisters, two daughters, and a wife. Breast cancer is going to impact people in my life."
|
|
― Matt Coffey, Ph.D., CEO, president and CEO, Oncolytics Biotech, Episode 136
|
|
|
"You can have the right idea. But, if you have it at the wrong time, it's not necessarily going to lead to anything ... Back in the late 80s, we had this radical idea that maybe we ought to study human disease in humans, because we weren't trying to cure mice."
|
|
― Michael Severino, M.D., CEO and board director, Tessera Therapeutics, Episode 138
|
|
|
"In my 20s, I was chasing the carrot like everybody does. Seeing the partners in their Porsches and thinking, oh, I want that. After I got cancer, I didn't ... I wanted to work at an oncology company."
|
|
― Keir Loiacono, Esq., CEO, BlueSphere Bio, Episode 140
|
|
|
|
|
|
|
![Business of Biotech Podcast]( "Business of Biotech Podcast") |
|
Created exclusively for the leaders of new and emerging biopharma firms, the Business of Biotech podcast tackles organizational, funding, HR, regulatory, production, and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success. Check out our episode archive. Business of Biotech is produced in partnership with Cytiva.
|
|
|
|
|
|
|
Ensure our newsletter reaches your inbox by following these whitelist instructions.
This newsletter is being sent to {{lead.Email Address}}. To cancel your subscription to the newsletter, please opt out.
|
|
© Copyright 2022 Vertmarkets, Inc. 5340 Fryling Rd Suite 100, Erie, PA 16510.
All rights reserved. All product names contained herein are the trademarks of their respective holders.
|
|
|
|
|
